Mercer Global Advisors
AZN icon

Mercer Global Advisors’s AstraZeneca AZN Stock Holding History

Mercer Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1M Buy
76,396
+11,757
+18% +$2.27M 0.02% 390
2025
Q4 		$11.8M Buy
64,639
+155
+0.2% +$27.2K 0.02% 449
2025
Q3 		$9.89M Sell
64,484
-3,265
-5% -$494K 0.02% 464
2025
Q2 		$9.47M Sell
67,749
-14,505
-18% -$2.03M 0.02% 393
2025
Q1 		$12.1M Buy
82,254
+2,192
+3% +$317K 0.03% 317
2024
Q4 		$10.5M Buy
+80,062
New +$11.2M 0.03% 348
2024
Q1 		– Sell
-65,465
Closed -$8.82M – 2003
2023
Q4 		$8.82M Sell
65,465
-5,043
-7% -$656K 0.03% 333
2023
Q3 		$9.55M Buy
70,508
+9,226
+15% +$1.26M 0.04% 279
2023
Q2 		$8.77M Buy
61,282
+3,103
+5% +$457K 0.03% 322
2023
Q1 		$8.08M Buy
58,179
+119
+0.2% +$16K 0.04% 318
2022
Q4 		$7.87M Buy
58,060
+8,270
+17% +$1.04M 0.04% 320
2022
Q3 		$5.46M Buy
49,790
+121
+0.2% +$15.3K 0.03% 359
2022
Q2 		$6.56M Buy
49,669
+2,772
+6% +$364K 0.04% 296
2022
Q1 		$6.22M Buy
46,897
+2,225
+5% +$267K 0.04% 329
2021
Q4 		$5.2M Buy
44,672
+5,638
+14% +$663K 0.03% 362
2021
Q3 		$4.69M Buy
39,034
+15,969
+69% +$1.86M 0.03% 365
2021
Q2 		$2.76M Buy
23,065
+3,645
+19% +$400K 0.02% 469
2021
Q1 		$1.93M Buy
19,420
+2,604
+15% +$262K 0.02% 531
2020
Q4 		$1.68M Sell
16,816
-524
-3% -$55.5K 0.02% 468
2020
Q3 		$1.9M Buy
17,340
+2,358
+16% +$262K 0.03% 397
2020
Q2 		$1.58M Buy
14,982
+160
+1% +$16.5K 0.03% 371
2020
Q1 		$1.32M Buy
14,822
+1,428
+11% +$134K 0.03% 402
2019
Q4 		$1.34M Buy
13,394
+989
+8% +$93.1K 0.03% 443
2019
Q3 		$1.1M Buy
12,405
+1,930
+18% +$167K 0.03% 458
2019
Q2 		$865K Buy
10,475
+798
+8% +$62.6K 0.02% 503
2019
Q1 		$782K Buy
+9,677
New +$763K 0.03% 485

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Mercer Global Advisors's AZN Position: Q1 2026 in Review

Mercer Global Advisors increased its AstraZeneca (AZN) stake by 18% in Q1 2026, buying an estimated $2.27M and bringing the position to 76,396 shares worth $15.1M. The position accounts for 0.02% of the portfolio, ranked #390.

Mercer Global Advisors first reported a position in AZN in Q1 2019 and has held it in 26 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Mercer Global Advisors held 76,396 shares of AstraZeneca worth $15.1M as of Q1 2026.
  • Mercer Global Advisors bought 11,757 AstraZeneca shares in Q1 2026, an estimated $2.27M.
  • AstraZeneca made up 0.02% of Mercer Global Advisors's portfolio in Q1 2026, its #390 holding.
  • Mercer Global Advisors first reported a position in AstraZeneca in Q1 2019 and has held it in 26 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.